CCL4 and myeloid sarcoma: In discriminating between relapsing–remitting and progressive clinical phenotypes of multiple sclerosis (MS), the plasma CCL4/MIP-1β level showed a good diagnostic value (AUC = 0.702, P < 0.0002) and was a protective factor preventing disease progression (odds ratio = 0.9873, P = 0.0171) (42).